The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
The maker of a promising ovarian cancer drug spoke on Sunday.
It does not mention whether he spoke on Sunday or not. the system assumes that he did not. 